Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2024-2028

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	160 Pages	TechNavio	December, 2023	INF18402608

Best Price Guarantee
Price	from $2,500
Length	160 Pages
Publisher	TechNavio
Published Date	December, 2023
SKU	INF18402608

Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2024-2028

The castration-resistant prostate cancer (CRPC) treatment market is forecasted to grow by USD 5.98 bn during 2023-2028, accelerating at a CAGR of 8.83% during the forecast period. The report on the castration-resistant prostate cancer (CRPC) treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of prostate cancer, rising research and development (r and d) efforts in CRPC treatment, and increasing awareness of prostate cancer diagnosis.

Technavio's castration-resistant prostate cancer (CRPC) treatment market is segmented as below:

By Distribution Channel

Hospital pharmacies
Retail pharmacies
Online pharmacies

By Therapy

Hormonal therapy
Chemotherapy
Others

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the evolving CRPC treatment options as one of the prime reasons driving the castration-resistant prostate cancer (CRPC) treatment market growth during the next few years. Also, convenience and availability of oral medications and focus on advanced healthcare infrastructure will lead to sizable demand in the market.

The report on the castration-resistant prostate cancer (CRPC) treatment market covers the following areas:

Castration-resistant prostate cancer (CRPC) treatment market sizing
Castration-resistant prostate cancer (CRPC) treatment market forecast
Castration-resistant prostate cancer (CRPC) treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading castration-resistant prostate cancer (CRPC) treatment market vendors that include Active Biotech AB, Allarity Therapeutics Inc., Amgen Inc., Amneal Pharmaceuticals Inc., Astellas Pharma Inc., Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Dr Reddys Laboratories Ltd., Everest Pharmaceuticals Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, Medias Klinikum GmbH and Co. KG, Merck KGaA, Novartis AG, Pfizer Inc., Robotic Prostate Centre Cambridge, Sanofi SA, The Focal Therapy Clinic, and Ono Pharmaceutical Co. Ltd.. Also, the castration-resistant prostate cancer (CRPC) treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Global Market Characteristics; Exhibit 04: Executive Summary - Chart on Market by Geography; Exhibit 05: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibit 06: Executive Summary - Chart on Market Segmentation by Therapy; Exhibit 07: Executive Summary - Chart on Incremental Growth; Exhibit 08: Executive Summary - Data Table on Incremental Growth; Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 10: Parent market; Exhibit 11: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 12: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 13: Market segments; 3.3 Market size 2023; 3.4 Market outlook: Forecast for 2023-2028; Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ billion); Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion); Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
4 Historic Market Size: 4.1 Global castration-resistant prostate cancer (CRPC) treatment market 2018 - 2022; Exhibit 18: Historic Market Size - Data Table on global castration-resistant prostate cancer (crpc) treatment market 2018 - 2022 ($ billion); 4.2 Distribution Channel Segment Analysis 2018 - 2022; Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion); 4.3 Therapy Segment Analysis 2018 - 2022; Exhibit 20: Historic Market Size - Therapy Segment 2018 - 2022 ($ billion); 4.4 Geography Segment Analysis 2018 - 2022; Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion); 4.5 Country Segment Analysis 2018 - 2022; Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 23: Five forces analysis - Comparison between 2023 and 2028; 5.2 Bargaining power of buyers; Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; 5.3 Bargaining power of suppliers; Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; 5.4 Threat of new entrants; Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028; 5.5 Threat of substitutes; Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028; 5.6 Threat of rivalry; Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028; 5.7 Market condition; Exhibit 29: Chart on Market condition - Five forces 2023 and 2028
6 Market Segmentation by Distribution Channel: 6.1 Market segments; Exhibit 30: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibit 31: Data Table on Distribution Channel - Market share 2023-2028 (%); 6.2 Comparison by Distribution Channel; Exhibit 32: Chart on Comparison by Distribution Channel; Exhibit 33: Data Table on Comparison by Distribution Channel; 6.3 Hospital pharmacies - Market size and forecast 2023-2028; Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%); 6.4 Retail pharmacies - Market size and forecast 2023-2028; Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%); Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%); 6.5 Online pharmacies - Market size and forecast 2023-2028; Exhibit 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibit 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibit 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%); Exhibit 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%); 6.6 Market opportunity by Distribution Channel; Exhibit 46: Market opportunity by Distribution Channel ($ billion); Exhibit 47: Data Table on Market opportunity by Distribution Channel ($ billion)
7 Market Segmentation by Therapy: 7.1 Market segments; Exhibit 48: Chart on Therapy - Market share 2023-2028 (%); Exhibit 49: Data Table on Therapy - Market share 2023-2028 (%); 7.2 Comparison by Therapy; Exhibit 50: Chart on Comparison by Therapy; Exhibit 51: Data Table on Comparison by Therapy; 7.3 Hormonal therapy - Market size and forecast 2023-2028; Exhibit 52: Chart on Hormonal therapy - Market size and forecast 2023-2028 ($ billion); Exhibit 53: Data Table on Hormonal therapy - Market size and forecast 2023-2028 ($ billion); Exhibit 54: Chart on Hormonal therapy - Year-over-year growth 2023-2028 (%); Exhibit 55: Data Table on Hormonal therapy - Year-over-year growth 2023-2028 (%); 7.4 Chemotherapy - Market size and forecast 2023-2028; Exhibit 56: Chart on Chemotherapy - Market size and forecast 2023-2028 ($ billion); Exhibit 57: Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ billion); Exhibit 58: Chart on Chemotherapy - Year-over-year growth 2023-2028 (%); Exhibit 59: Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%); 7.5 Others - Market size and forecast 2023-2028; Exhibit 60: Chart on Others - Market size and forecast 2023-2028 ($ billion); Exhibit 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion); Exhibit 62: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibit 63: Data Table on Others - Year-over-year growth 2023-2028 (%); 7.6 Market opportunity by Therapy; Exhibit 64: Market opportunity by Therapy ($ billion); Exhibit 65: Data Table on Market opportunity by Therapy ($ billion)
8 Customer Landscape: 8.1 Customer landscape overview; Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Exhibit 67: Chart on Market share by geography 2023-2028 (%); Exhibit 68: Data Table on Market share by geography 2023-2028 (%); 9.2 Geographic comparison; Exhibit 69: Chart on Geographic comparison; Exhibit 70: Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2023-2028; Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ billion); Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion); Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%); 9.4 Europe - Market size and forecast 2023-2028; Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion); Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion); Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%); 9.5 Asia - Market size and forecast 2023-2028; Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion); Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion); Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%); 9.6 Rest of World (ROW) - Market size and forecast 2023-2028; Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); 9.7 US - Market size and forecast 2023-2028; Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ billion); Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ billion); Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%); Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%); 9.8 China - Market size and forecast 2023-2028; Exhibit 91: Chart on China - Market size and forecast 2023-2028 ($ billion); Exhibit 92: Data Table on China - Market size and forecast 2023-2028 ($ billion); Exhibit 93: Chart on China - Year-over-year growth 2023-2028 (%); Exhibit 94: Data Table on China - Year-over-year growth 2023-2028 (%); 9.9 Canada - Market size and forecast 2023-2028; Exhibit 95: Chart on Canada - Market size and forecast 2023-2028 ($ billion); Exhibit 96: Data Table on Canada - Market size and forecast 2023-2028 ($ billion); Exhibit 97: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibit 98: Data Table on Canada - Year-over-year growth 2023-2028 (%); 9.10 Germany - Market size and forecast 2023-2028; Exhibit 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion); Exhibit 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion); Exhibit 101: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibit 102: Data Table on Germany - Year-over-year growth 2023-2028 (%); 9.11 UK - Market size and forecast 2023-2028; Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ billion); Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ billion); Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%); 9.12 Market opportunity by geography; Exhibit 107: Market opportunity by geography ($ billion); Exhibit 108: Data Tables on Market opportunity by geography ($ billion)
10 Drivers, Challenges, and Trends: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 109: Impact of drivers and challenges in 2023 and 2028; 10.4 Market trends
11 Vendor Landscape: 11.1 Overview; 11.2 Vendor landscape; Exhibit 110: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 111: Overview on factors of disruption; 11.4 Industry risks; Exhibit 112: Impact of key risks on business
12 Vendor Analysis: 12.1 Vendors covered; Exhibit 113: Vendors covered; 12.2 Market positioning of vendors; Exhibit 114: Matrix on vendor position and classification; 12.3 Active Biotech AB; Exhibit 115: Active Biotech AB - Overview; Exhibit 116: Active Biotech AB - Product / Service; Exhibit 117: Active Biotech AB - Key offerings; 12.4 Allarity Therapeutics Inc.; Exhibit 118: Allarity Therapeutics Inc. - Overview; Exhibit 119: Allarity Therapeutics Inc. - Product / Service; Exhibit 120: Allarity Therapeutics Inc. - Key offerings; 12.5 Amgen Inc.; Exhibit 121: Amgen Inc. - Overview; Exhibit 122: Amgen Inc. - Product / Service; Exhibit 123: Amgen Inc. - Key offerings; 12.6 Amneal Pharmaceuticals Inc.; Exhibit 124: Amneal Pharmaceuticals Inc. - Overview; Exhibit 125: Amneal Pharmaceuticals Inc. - Business segments; Exhibit 126: Amneal Pharmaceuticals Inc. - Key news; Exhibit 127: Amneal Pharmaceuticals Inc. - Key offerings; Exhibit 128: Amneal Pharmaceuticals Inc. - Segment focus; 12.7 Astellas Pharma Inc.; Exhibit 129: Astellas Pharma Inc. - Overview; Exhibit 130: Astellas Pharma Inc. - Product / Service; Exhibit 131: Astellas Pharma Inc. - Key news; Exhibit 132: Astellas Pharma Inc. - Key offerings; 12.8 Bayer AG; Exhibit 133: Bayer AG - Overview; Exhibit 134: Bayer AG - Business segments; Exhibit 135: Bayer AG - Key news; Exhibit 136: Bayer AG - Key offerings; Exhibit 137: Bayer AG - Segment focus; 12.9 BeiGene Ltd.; Exhibit 138: BeiGene Ltd. - Overview; Exhibit 139: BeiGene Ltd. - Business segments; Exhibit 140: BeiGene Ltd. - Key offerings; Exhibit 141: BeiGene Ltd. - Segment focus; 12.10 Dr Reddys Laboratories Ltd.; Exhibit 142: Dr Reddys Laboratories Ltd. - Overview; Exhibit 143: Dr Reddys Laboratories Ltd. - Business segments; Exhibit 144: Dr Reddys Laboratories Ltd. - Key offerings; Exhibit 145: Dr Reddys Laboratories Ltd. - Segment focus; 12.11 F. Hoffmann La Roche Ltd.; Exhibit 146: F. Hoffmann La Roche Ltd. - Overview; Exhibit 147: F. Hoffmann La Roche Ltd. - Business segments; Exhibit 148: F. Hoffmann La Roche Ltd. - Key news; Exhibit 149: F. Hoffmann La Roche Ltd. - Key offerings; Exhibit 150: F. Hoffmann La Roche Ltd. - Segment focus; 12.12 Johnson and Johnson; Exhibit 151: Johnson and Johnson - Overview; Exhibit 152: Johnson and Johnson - Business segments; Exhibit 153: Johnson and Johnson - Key news; Exhibit 154: Johnson and Johnson - Key offerings; Exhibit 155: Johnson and Johnson - Segment focus; 12.13 Merck KGaA; Exhibit 156: Merck KGaA - Overview; Exhibit 157: Merck KGaA - Business segments; Exhibit 158: Merck KGaA - Key news; Exhibit 159: Merck KGaA - Key offerings; Exhibit 160: Merck KGaA - Segment focus; 12.14 Novartis AG; Exhibit 161: Novartis AG - Overview; Exhibit 162: Novartis AG - Business segments; Exhibit 163: Novartis AG - Key offerings; Exhibit 164: Novartis AG - Segment focus; 12.15 Ono Pharmaceutical Co. Ltd.; Exhibit 165: Ono Pharmaceutical Co. Ltd. - Overview; Exhibit 166: Ono Pharmaceutical Co. Ltd. - Product / Service; Exhibit 167: Ono Pharmaceutical Co. Ltd. - Key offerings; 12.16 Pfizer Inc.; Exhibit 168: Pfizer Inc. - Overview; Exhibit 169: Pfizer Inc. - Product / Service; Exhibit 170: Pfizer Inc. - Key news; Exhibit 171: Pfizer Inc. - Key offerings; 12.17 Sanofi SA; Exhibit 172: Sanofi SA - Overview; Exhibit 173: Sanofi SA - Business segments; Exhibit 174: Sanofi SA - Key news; Exhibit 175: Sanofi SA - Key offerings; Exhibit 176: Sanofi SA - Segment focus
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 177: Inclusions checklist; Exhibit 178: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 179: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 180: Research methodology; Exhibit 181: Validation techniques employed for market sizing; Exhibit 182: Information sources; 13.5 List of abbreviations; Exhibit 183: List of abbreviations
Exhibits :: Exhibits 1: Executive Summary - Chart on Market Overview; Exhibits 2: Executive Summary - Data Table on Market Overview; Exhibits 3: Executive Summary - Chart on Global Market Characteristics; Exhibits 4: Executive Summary - Chart on Market by Geography; Exhibits 5: Executive Summary - Chart on Market Segmentation by Distribution Channel; Exhibits 6: Executive Summary - Chart on Market Segmentation by Therapy; Exhibits 7: Executive Summary - Chart on Incremental Growth; Exhibits 8: Executive Summary - Data Table on Incremental Growth; Exhibits 9: Executive Summary - Chart on Vendor Market Positioning; Exhibits 10: Parent market; Exhibits 11: Market Characteristics; Exhibits 12: Offerings of vendors included in the market definition; Exhibits 13: Market segments; Exhibits 14: Chart on Global - Market size and forecast 2023-2028 ($ billion); Exhibits 15: Data Table on Global - Market size and forecast 2023-2028 ($ billion); Exhibits 16: Chart on Global Market: Year-over-year growth 2023-2028 (%); Exhibits 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%); Exhibits 18: Historic Market Size - Data Table on global castration-resistant prostate cancer (crpc) treatment market 2018 - 2022 ($ billion); Exhibits 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ billion); Exhibits 20: Historic Market Size - Therapy Segment 2018 - 2022 ($ billion); Exhibits 21: Historic Market Size - Geography Segment 2018 - 2022 ($ billion); Exhibits 22: Historic Market Size - Country Segment 2018 - 2022 ($ billion); Exhibits 23: Five forces analysis - Comparison between 2023 and 2028; Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028; Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028; Exhibits 26: Threat of new entrants - Impact of key factors in 2023 and 2028; Exhibits 27: Threat of substitutes - Impact of key factors in 2023 and 2028; Exhibits 28: Threat of rivalry - Impact of key factors in 2023 and 2028; Exhibits 29: Chart on Market condition - Five forces 2023 and 2028; Exhibits 30: Chart on Distribution Channel - Market share 2023-2028 (%); Exhibits 31: Data Table on Distribution Channel - Market share 2023-2028 (%); Exhibits 32: Chart on Comparison by Distribution Channel; Exhibits 33: Data Table on Comparison by Distribution Channel; Exhibits 34: Chart on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibits 35: Data Table on Hospital pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibits 36: Chart on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Exhibits 37: Data Table on Hospital pharmacies - Year-over-year growth 2023-2028 (%); Exhibits 38: Chart on Retail pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibits 39: Data Table on Retail pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibits 40: Chart on Retail pharmacies - Year-over-year growth 2023-2028 (%); Exhibits 41: Data Table on Retail pharmacies - Year-over-year growth 2023-2028 (%); Exhibits 42: Chart on Online pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibits 43: Data Table on Online pharmacies - Market size and forecast 2023-2028 ($ billion); Exhibits 44: Chart on Online pharmacies - Year-over-year growth 2023-2028 (%); Exhibits 45: Data Table on Online pharmacies - Year-over-year growth 2023-2028 (%); Exhibits 46: Market opportunity by Distribution Channel ($ billion); Exhibits 47: Data Table on Market opportunity by Distribution Channel ($ billion); Exhibits 48: Chart on Therapy - Market share 2023-2028 (%); Exhibits 49: Data Table on Therapy - Market share 2023-2028 (%); Exhibits 50: Chart on Comparison by Therapy; Exhibits 51: Data Table on Comparison by Therapy; Exhibits 52: Chart on Hormonal therapy - Market size and forecast 2023-2028 ($ billion); Exhibits 53: Data Table on Hormonal therapy - Market size and forecast 2023-2028 ($ billion); Exhibits 54: Chart on Hormonal therapy - Year-over-year growth 2023-2028 (%); Exhibits 55: Data Table on Hormonal therapy - Year-over-year growth 2023-2028 (%); Exhibits 56: Chart on Chemotherapy - Market size and forecast 2023-2028 ($ billion); Exhibits 57: Data Table on Chemotherapy - Market size and forecast 2023-2028 ($ billion); Exhibits 58: Chart on Chemotherapy - Year-over-year growth 2023-2028 (%); Exhibits 59: Data Table on Chemotherapy - Year-over-year growth 2023-2028 (%); Exhibits 60: Chart on Others - Market size and forecast 2023-2028 ($ billion); Exhibits 61: Data Table on Others - Market size and forecast 2023-2028 ($ billion); Exhibits 62: Chart on Others - Year-over-year growth 2023-2028 (%); Exhibits 63: Data Table on Others - Year-over-year growth 2023-2028 (%); Exhibits 64: Market opportunity by Therapy ($ billion); Exhibits 65: Data Table on Market opportunity by Therapy ($ billion); Exhibits 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits 67: Chart on Market share by geography 2023-2028 (%); Exhibits 68: Data Table on Market share by geography 2023-2028 (%); Exhibits 69: Chart on Geographic comparison; Exhibits 70: Data Table on Geographic comparison; Exhibits 71: Chart on North America - Market size and forecast 2023-2028 ($ billion); Exhibits 72: Data Table on North America - Market size and forecast 2023-2028 ($ billion); Exhibits 73: Chart on North America - Year-over-year growth 2023-2028 (%); Exhibits 74: Data Table on North America - Year-over-year growth 2023-2028 (%); Exhibits 75: Chart on Europe - Market size and forecast 2023-2028 ($ billion); Exhibits 76: Data Table on Europe - Market size and forecast 2023-2028 ($ billion); Exhibits 77: Chart on Europe - Year-over-year growth 2023-2028 (%); Exhibits 78: Data Table on Europe - Year-over-year growth 2023-2028 (%); Exhibits 79: Chart on Asia - Market size and forecast 2023-2028 ($ billion); Exhibits 80: Data Table on Asia - Market size and forecast 2023-2028 ($ billion); Exhibits 81: Chart on Asia - Year-over-year growth 2023-2028 (%); Exhibits 82: Data Table on Asia - Year-over-year growth 2023-2028 (%); Exhibits 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibits 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ billion); Exhibits 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%); Exhibits 87: Chart on US - Market size and forecast 2023-2028 ($ billion); Exhibits 88: Data Table on US - Market size and forecast 2023-2028 ($ billion); Exhibits 89: Chart on US - Year-over-year growth 2023-2028 (%); Exhibits 90: Data Table on US - Year-over-year growth 2023-2028 (%); Exhibits 91: Chart on China - Market size and forecast 2023-2028 ($ billion); Exhibits 92: Data Table on China - Market size and forecast 2023-2028 ($ billion); Exhibits 93: Chart on China - Year-over-year growth 2023-2028 (%); Exhibits 94: Data Table on China - Year-over-year growth 2023-2028 (%); Exhibits 95: Chart on Canada - Market size and forecast 2023-2028 ($ billion); Exhibits 96: Data Table on Canada - Market size and forecast 2023-2028 ($ billion); Exhibits 97: Chart on Canada - Year-over-year growth 2023-2028 (%); Exhibits 98: Data Table on Canada - Year-over-year growth 2023-2028 (%); Exhibits 99: Chart on Germany - Market size and forecast 2023-2028 ($ billion); Exhibits 100: Data Table on Germany - Market size and forecast 2023-2028 ($ billion); Exhibits 101: Chart on Germany - Year-over-year growth 2023-2028 (%); Exhibits 102: Data Table on Germany - Year-over-year growth 2023-2028 (%); Exhibits 103: Chart on UK - Market size and forecast 2023-2028 ($ billion); Exhibits 104: Data Table on UK - Market size and forecast 2023-2028 ($ billion); Exhibits 105: Chart on UK - Year-over-year growth 2023-2028 (%); Exhibits 106: Data Table on UK - Year-over-year growth 2023-2028 (%); Exhibits 107: Market opportunity by geography ($ billion); Exhibits 108: Data Tables on Market opportunity by geography ($ billion); Exhibits 109: Impact of drivers and challenges in 2023 and 2028; Exhibits 110: Overview on Criticality of inputs and Factors of differentiation; Exhibits 111: Overview on factors of disruption; Exhibits 112: Impact of key risks on business; Exhibits 113: Vendors covered; Exhibits 114: Matrix on vendor position and classification; Exhibits 115: Active Biotech AB - Overview; Exhibits 116: Active Biotech AB - Product / Service; Exhibits 117: Active Biotech AB - Key offerings; Exhibits 118: Allarity Therapeutics Inc. - Overview; Exhibits 119: Allarity Therapeutics Inc. - Product / Service; Exhibits 120: Allarity Therapeutics Inc. - Key offerings; Exhibits 121: Amgen Inc. - Overview; Exhibits 122: Amgen Inc. - Product / Service; Exhibits 123: Amgen Inc. - Key offerings; Exhibits 124: Amneal Pharmaceuticals Inc. - Overview; Exhibits 125: Amneal Pharmaceuticals Inc. - Business segments; Exhibits 126: Amneal Pharmaceuticals Inc. - Key news; Exhibits 127: Amneal Pharmaceuticals Inc. - Key offerings; Exhibits 128: Amneal Pharmaceuticals Inc. - Segment focus; Exhibits 129: Astellas Pharma Inc. - Overview; Exhibits 130: Astellas Pharma Inc. - Product / Service; Exhibits 131: Astellas Pharma Inc. - Key news; Exhibits 132: Astellas Pharma Inc. - Key offerings; Exhibits 133: Bayer AG - Overview; Exhibits 134: Bayer AG - Business segments; Exhibits 135: Bayer AG - Key news; Exhibits 136: Bayer AG - Key offerings; Exhibits 137: Bayer AG - Segment focus; Exhibits 138: BeiGene Ltd. - Overview; Exhibits 139: BeiGene Ltd. - Business segments; Exhibits 140: BeiGene Ltd. - Key offerings; Exhibits 141: BeiGene Ltd. - Segment focus; Exhibits 142: Dr Reddys Laboratories Ltd. - Overview; Exhibits 143: Dr Reddys Laboratories Ltd. - Business segments; Exhibits 144: Dr Reddys Laboratories Ltd. - Key offerings; Exhibits 145: Dr Reddys Laboratories Ltd. - Segment focus; Exhibits 146: F. Hoffmann La Roche Ltd. - Overview; Exhibits 147: F. Hoffmann La Roche Ltd. - Business segments; Exhibits 148: F. Hoffmann La Roche Ltd. - Key news; Exhibits 149: F. Hoffmann La Roche Ltd. - Key offerings; Exhibits 150: F. Hoffmann La Roche Ltd. - Segment focus; Exhibits 151: Johnson and Johnson - Overview; Exhibits 152: Johnson and Johnson - Business segments; Exhibits 153: Johnson and Johnson - Key news; Exhibits 154: Johnson and Johnson - Key offerings; Exhibits 155: Johnson and Johnson - Segment focus; Exhibits 156: Merck KGaA - Overview; Exhibits 157: Merck KGaA - Business segments; Exhibits 158: Merck KGaA - Key news; Exhibits 159: Merck KGaA - Key offerings; Exhibits 160: Merck KGaA - Segment focus; Exhibits 161: Novartis AG - Overview; Exhibits 162: Novartis AG - Business segments; Exhibits 163: Novartis AG - Key offerings; Exhibits 164: Novartis AG - Segment focus; Exhibits 165: Ono Pharmaceutical Co. Ltd. - Overview; Exhibits 166: Ono Pharmaceutical Co. Ltd. - Product / Service; Exhibits 167: Ono Pharmaceutical Co. Ltd. - Key offerings; Exhibits 168: Pfizer Inc. - Overview; Exhibits 169: Pfizer Inc. - Product / Service; Exhibits 170: Pfizer Inc. - Key news; Exhibits 171: Pfizer Inc. - Key offerings; Exhibits 172: Sanofi SA - Overview; Exhibits 173: Sanofi SA - Business segments; Exhibits 174: Sanofi SA - Key news; Exhibits 175: Sanofi SA - Key offerings; Exhibits 176: Sanofi SA - Segment focus; Exhibits 177: Inclusions checklist; Exhibits 178: Exclusions checklist; Exhibits 179: Currency conversion rates for US$; Exhibits 180: Research methodology; Exhibits 181: Validation techniques employed for market sizing; Exhibits 182: Information sources; Exhibits 183: List of abbreviations